0000899243-18-017794.txt : 20180622
0000899243-18-017794.hdr.sgml : 20180622
20180622211154
ACCESSION NUMBER: 0000899243-18-017794
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180620
FILED AS OF DATE: 20180622
DATE AS OF CHANGE: 20180622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pomerantz Roger
CENTRAL INDEX KEY: 0001614936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 18915844
MAIL ADDRESS:
STREET 1: 711 HARVEST HILL ROAD
CITY: CHALFONT
STATE: PA
ZIP: 18914
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-20
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001614936
Pomerantz Roger
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2018-06-20
4
S
0
26492
9.3255
D
297812
D
Common Stock
2018-06-21
4
S
0
18987
9.0638
D
278825
D
Common Stock
2018-06-22
4
S
0
40057
9.3557
D
238768
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Thomas J. DesRosier, Attorney-in-Fact
2018-06-22